Cantor Fitzgerald Reaffirms Overweight Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)
Cantor Fitzgerald restated their overweight rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $480.00 price target on the pharmaceutical company’s stock. Several other equities analysts also recently weighed in on VRTX. Stifel Nicolaus lifted their price target on shares of […]
Cantor Fitzgerald restated their overweight rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $480.00 price target on the pharmaceutical company’s stock. Several other equities analysts also recently weighed in on VRTX. Stifel Nicolaus lifted their price target on shares of […]
